News Archive
Successful completion of three year trial programme for 3AEY
Eden Research is pleased to announce today it has successfully completed its three year trial programme for 3AEY. Since 2005, Eden has conducted over thirty efficacy trials for its EU registration programme using leading contract research organisation Eurofins Agrisearch.
The data collected has demonstrated that Eden's low environmental impact product 3AEY is both cost effective and efficacious when compared to established botrytis control market standards Rovral(tm) and Scala(tm) on wine grapes.
More recently, in the 2007 programme work concentrated in two new areas:
- Commercial efficacy comparisons with popular new generation premium products Frupica(tm), Teldor(tm)and Switch(tm); and
- Testing on grapes destined for the valuable fresh/dessert market, where the appearance of the crop further affects potential financial returns.
The Results
Disease control - In three efficacy trials conducted in Greece last season by Eurofins Agrisearch, Eden's Botrytis control product 3AEY, used four times as a preventative treatment, showed outstanding results when compared with a variety of established products applied at commercially recommended doses:
- In two trials on dessert grapes it performed significantly better at reducing disease, than the established market standards iprodione (Rovral(tm)) and pyrimethanil (Scala(tm)); whilst
- In a trial on wine grapes, disease severity was reduced by over 92%, statistically identical to the increasingly popular new generation products, Frupica(tm)(mepanipyrim), Teldor(tm)(fenhexamid), and Switch(tm) (cyprodinil & fludioxonil), whilst under high disease pressure.
Fruit quality - In the same three trials, when fruit quality was assessed, Eden product 3AEY produced the highest % of premium grade fruit in all cases, and the smallest fraction of Class 2 (lowest quality) fruit.
These trends were particularly noticeable (and statistically significant) when compared to the new market leaders Frupica(tm), Teldor(tm) and Switch(tm). The out-turn of premium quality fruit from the 3AEY treated plots in this trial reached 38.5% at harvest, approaching double that of the three new industry standards (which only achieved out-turns of 23.5%, 20.2% and 28.3% premium grade respectively). Losses to the lowest grade (Grade 2) fruit were also much reduced when treated with 3AEY at 6%, compared to 18.5%, 26.2% and 17.7% respectively with the standard treatments.
Commenting, Tim Griffiths Eden's CEO said:
"We feel that these exciting results will help our commercial partners to achieve a strong position in the market for grape botrytis control products.
"The data suggests that 3AEY could become the product of first choice for commercial growers, with improved fruit quality reinforcing our product's reliability and attractive natural ingredient profile.
"We therefore intend to implement further marketing studies in Southern Europe this year to reinforce these data. We intend to conduct further comparative studies to assist our marketing partners."
For further information, please contact:
Tim Griffiths, Chief Executive, Eden Research plc
T: 01993 868844
Matthew Robinson, JM Finn Capital Markets Ltd
T : 020 7600 1658
Jonathon Brill/Caroline Stewart, Financial Dynamics
T: 020 7831 3113
About Eden Research plc
About Eden Research plc
Eden Research plc is a UK publicly listed company on the PLUS Market, specialising in the development of agrochemical products and intellectual property through licensing and marketing agreements.
Eden is focused on developing products for the agricultural sector through the application of terpene chemistry and other patented environmentally friendly technologies. Eden is currently working alongside universities and partner companies in developing its product portfolio towards commercialisation.
For further information please visit www.edenresearch.com.